Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares (CANF) Stock Price

CANFStock

$3.32−72.16%52W

Market Cap$7.11M

P/E—

PEG Ratio—

Div yield—

Beta-0.50

CANF Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-38.53%

Price vs S&P 500 (4W)-1.25%

VGM Score37.61

Book Value / Share (Quarterly)$2.14

P/TBV (Annual)1.99x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-41.59%

Cash Flow / Share (Quarterly)$-3.42

Price vs S&P 500 (YTD)-111.38%

Net Profit Margin (TTM)-2422.41%

EPS (TTM)$-10.30

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-10.30

Revenue Growth (5Y)-12.49%

EPS (Annual)$-5.97

ROI (Annual)-175.75%

Gross Margin (Annual)90.62%

Net Profit Margin (5Y Avg)-1083.32%

Cash / Share (Quarterly)$2.11

Revenue Growth QoQ (YoY)-39.91%

ROA (Last FY)-103.30%

Revenue Growth TTM (YoY)-38.69%

EBITD / Share (TTM)$-10.70

ROE (5Y Avg)-151.64%

Operating Margin (TTM)-2446.13%

Cash Flow / Share (Annual)$-3.42

P/B Ratio1.32x

P/B Ratio (Quarterly)4.71x

Net Income / Employee (Annual)$-1,965,600

EV / Revenue (TTM)3.10x

Net Interest Coverage (TTM)-165.77x

ROA (TTM)-170.64%

EPS Incl Extra (Annual)$-5.97

Current Ratio (Annual)3.46x

Quick Ratio (Quarterly)3.13x

3-Month Avg Trading Volume0.03M

52-Week Price Return-72.16%

Revenue / Employee (TTM)$121,400

Tangible BV / Share (Quarterly)$0.03

P/S Ratio (Annual)18.29x

Asset Turnover (Annual)0.04x

52-Week High$9000000.00

Operating Margin (5Y Avg)-1099.72%

EPS Excl Extra (Annual)$-5.97

CapEx CAGR (5Y)-40.13%

Tangible BV CAGR (5Y)-2.26%

26-Week Price Return-27.29%

Quick Ratio (Annual)3.15x

13-Week Price Return1.80%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.46x

Enterprise Value$1.88M

Revenue / Share Growth (5Y)59.81%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)176.98%

Revenue / Employee (Annual)$81,000

Pretax Margin (Annual)-2426.67%

Cash / Share (Annual)$2.11

3-Month Return Std Dev134.67%

Net Income / Employee (TTM)$-2,940,800

ROE (Last FY)-175.75%

Net Interest Coverage (Annual)-30.79x

EPS Basic Excl Extra (Annual)$-5.97

Receivables Turnover (TTM)0.23x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-10.30

Receivables Turnover (Annual)71.40x

ROI (TTM)-300.82%

P/S Ratio (TTM)12.20x

Pretax Margin (5Y Avg)-1083.30%

Revenue / Share (Annual)$0.25

Tangible BV / Share (Annual)$0.02

Price vs S&P 500 (52W)-70.54%

Year-to-Date Return-99.99%

5-Day Price Return-5.81%

EPS Normalized (Annual)$-5.97

ROA (5Y Avg)-87.60%

Net Profit Margin (Annual)-2426.67%

Month-to-Date Return-1.93%

EBITD / Share (Annual)$-6.03

Operating Margin (Annual)-2456.79%

ROI (5Y Avg)-151.64%

EPS Basic Excl Extra (TTM)$-10.30

P/TBV (Quarterly)1.05x

P/B Ratio (Annual)4.71x

Pretax Margin (TTM)-2422.41%

Book Value / Share (Annual)$2.14

Price vs S&P 500 (13W)-0.99%

Beta-0.50x

Revenue / Share (TTM)$0.37

ROE (TTM)-300.82%

52-Week Low$374.00

vGradeC

gGradeF

mGradeD

vgmGradeD

CANF Earnings Surprise History

Q2 250.00est. -2.40

CANF Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
CANFCan-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares	C	F	D	$3.32
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares

Can-Fite Biopharma is a clinical-stage biopharmaceutical company developing oral small-molecule drugs targeting the A3 adenosine receptor for cancer, inflammatory diseases, and liver disorders. The company's platform exploits selective A3AR expression in diseased cells, potentially enabling safer therapeutic efficacy. Its pipeline includes multiple candidates in Phase II and Phase III clinical development, including Namodenoson, Piclidenoson, and CF602.